United States: Federal Circuit Clarifies Obviousness-Type Double Patenting Between Products And Methods

Last Updated: October 16 2012
Article by Leon Y. Lum

In Eli Lilly and Company v. Teva Parenteral Medicines, Inc., the Federal Circuit affirmed the district court's decision that Eli Lilly's patent to pemetrexed is not invalid for obviousness-type double patenting. The Federal Circuit's decision provides important guidance on one of the most complex areas of U.S. patent jurisprudence, and explains how information in the specification can be used in a double patenting analysis, discusses when obviousness-type double patenting may arise between product and method claims, and notes that unexpected results may be relevant to obviousness-type double patenting.

The Patent at Issue

The patent at issue, U.S. Patent 5,344,932, relates to Eli Lilly's Alimta® (pemetrexed) product, which is used in the treatment of advanced nonsquamous non-small cell lung cancer. Claims 1, 2 and 7 recite Markush groups that encompass a number of structurally related antifolate compounds, including pemetrexed. Claim 3 is directed specifically to pemetrexed, whose structure is reproduced below:

Pemetrexed and the other structurally related antifolates claimed in the '932 patent exhibit anti-cancer activity by inhibiting folate-specific enzymes that selectively regulate DNA synthesis (TS inhibition), thereby inhibiting cancer cell growth and division. In contrast, prior art antifolates inhibit both DNA and RNA synthesis, which can be toxic for normal cells utilizing RNA synthesis.

The '932 patent is part of a family of patents that includes U.S. Patent 5,028,608 and U.S. Patent 5,248,775, both of which issued prior to the issuance of the '932 patent.

Claim 3 of the '608 patent recites an antifolate compound which differs from pemetrexed only by having a five-member thiophene ring in the aryl region, as opposed to pemetrexed's six-member phenyl ring:

Claim 7 of the '775 patent recites an intermediate compound which the '775 patent teaches can be used to produce pemetrexed.

The District Court Decision

Three generic drug manufacturers, Teva Parenteral Medicines, Inc., Barr Laboratories, Inc. and APP Pharmaceuticals, LLC (collectively, "Teva"), filed abbreviated new drug applications (ANDAs) with paragraph IV certifications alleging that the '932 patent is invalid, unenforceable or not infringed by their proposed generic products. The invalidity issue before the Federal Circuit was whether the '932 patent is invalid for obviousness-type double patenting over claim 3 of the '608 patent or claim 7 of the '775 patent.

Teva presented the following arguments:

The '608 Patent: Pemetrexed is obvious over the '608 Compound claimed in the '608 patent because prior art antifolate compounds had a phenyl group in the aryl position (the sole difference between pemetrexed and the '608 Compound), providing "conventional wisdom" to substitute a phenyl group for the thiophene ring of the '608 Compound.

The '775 Patent: Pemetrexed is an obvious use for the '775 Intermediate, particularly when viewed in light of the '775 specification, which describes a process of synthesizing pemetrexed using the '775 Intermediate. Even without that disclosure, a skilled chemist presented with the '775 Intermediate "would have recognized pemetrexed as an obvious end product."

The district court disagreed with Teva's arguments.

Addressing the '608 patent, the district court stated that a skilled artisan would not have only focused on the aryl region, as Teva contends, but "would have pursued changes outside of the aryl region to improve TS inhibition and would have avoided introducing a phenyl group into the '608 Compound based on previous reports of toxicity with analogous antifolate structures." For example, methotrexate, an antifolate compound with a phenyl group at the aryl position, was well-known in the art and exhibits undesirable side effects related to toxicity.

Addressing the '775 patent, the district court noted that the '932 patent does not claimthe '775 Intermediate, and so "the teachings from the '775 patent's specification were inapplicable." The court also stated that pemetrexed would not have been obvious over the '775 Intermediate because of the "many possible choices" available to the skilled artisan for using the intermediate.

The Federal Circuit Decision

Teva presented similar arguments to the Federal Circuit:

The '608 Patent

  • Citing the Federal Circuit's 2009 decision in Amgen Inc. v. Hoffman-La Roche Ltd., Teva argued that the district court erred because "the correct analysis involves only the differences between the claims at issue, so that any features held in common between the claims – in this case, all but the aryl regions of the '608 Compound and pemetrexed – would be excluded from consideration."
  • Teva repeated its "conventional wisdom" argument based on prior art antifolates.
  • Teva argued that the district court erred in finding "a phenyl group undesirable within the structural context of the '608 Compound."
  • Teva argued that "principles of bioisosterism" would have led to the replacement of the thiophene group with a phenyl group.

The '775 Patent

  • Citing the CCPA's 1931 decision in In re Byck, and the Federal Circuit's 2010 decision in Sun Pharmaceutical Industries, Ltd., v. Eli Lilly & Co., Teva argued that the '775 patent's disclosure of using the '775 Intermediate to make pemetrexed renders obvious the '932 patent claim to pemetrexed.

The Federal Circuit rejected Teva's arguments.

The Federal Circuit noted that, as in any obviousness analysis, in an obviousness-type double patenting analysis, differences between the claims "cannot be considered in isolation – the claims must be considered as a whole." Thus, the Federal Circuit concluded that the district court "did not err by examining whether one of ordinary skill in the art would have been motivated to modify the '608 Compound to create pemetrexed, considering the compounds as a whole."

On the merits, the Federal Circuit emphasized that an obviousness-type double patenting analysis in a chemical context requires "some reason" for modifying a chemical structure, coupled with "a reasonable expectation of success" in doing so. The Federal Circuit noted that Lilly had presented evidence of "contemporary experience and understanding in the TS field" that substituting a phenyl group into the '608 Compound would have been undesirable, given "earlier reports of associated inefficacy and toxicity." The Federal Circuit found no error in the way the district court weighed the evidence and decided the issue in Lilly's favor.

Addressing the '775 patent, the Federal Circuit emphasized that an obvious-type double patenting analysis should rest on a comparison between the claims at issue, "with the earlier patent's written description considered only to the extent necessary to construe its claims." This is because

The focus of the obviousness-type double patenting doctrine ... rests on preventing a patentee from claiming an obvious variant of what it has previously claimed, not what it has previously disclosed.

The Federal Circuit addressed Byck and Sun and two other cases where the specification of the earlier patent was relied upon to invalidate the claims of the later patent under the doctrine of obviousness-type double patenting: Geneva Pharmaceuticals, Inc. v. GlaxoSmithKline PLC (Fed. Cir. 2003) and Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2008). In Byck, the patent at issue claimed an insulated coil coated with a phenol-oil composition, but the patentee had already patented the same phenol-oil composition in a patent that disclosed its use for coating coils. In Sun, the patent at issue claimed methods of using gemcitabine for treating cancer, but the earlier patent claimed gemcitabine and taught that it was useful to treat cancer. In Geneva, the patentee claimed methods of using clavulanic acid for treating antibiotic-resistant bacteria, but owned an earlier patent that claimed clavulanic acid and disclosed its use against the same bacteria. In Pfizer, the patent at issue claimed methods of administering an anti-inflammatory drug, but the patentee had previously patented the same drug in a patent that disclosed its use in the same methods.

The Federal Circuit characterized these cases as representing "a limited exception:"

Byck, Geneva, Pfizer, and Sun thus "address the situation in which an earlier patent claims a compound, disclosing the utility of that compound in the specification, and a later patent claims a method of using that compound for a particular use described in the specification of the earlier patent." .... Furthermore, in each of those cases, the claims held to be patentably indistinct had in common the same compound or composition—that is, each subsequently patented "use" constituted a, or the, disclosed use for the previously claimed substance.

The Federal Circuit distinguished the claims at issue:

  • pemetrexed and the '775 Intermediate are two distinct compounds
  • pemetrexed can be made by many different processes that do not require the '775 Intermediate
  • the '775 patent "offered no protection for pemetrexed" and the '932 patent does "not incorporate or require use of the '775 Intermediate"

Accordingly, the Federal Circuit affirmed the district court's decision finding that the '932 patent claims are not invalid for obviousness-type double patenting.

Unexpected Results

In a portion of the decision that might be dicta itself, the Federal Circuit noted that the district court's refusal to consider Lilly's evidence of unexpected results appears to have been based on misunderstood dicta in Geneva. In an effort to clarify this aspect of obviousness-type double patenting jurisprudence, the Federal Circuit stated:

[T]he district court relied on a footnote in Geneva, in which we remarked only that inquiry into secondary considerations is not requiredin every obviousness-type double patenting analysis, not that such evidence is off-limits or irrelevant. .... The district court's categorical repudiation of Lilly's evidence was therefore erroneous. When offered, such evidence should be considered; a fact-finder "must withhold judgment on an obviousness challenge until it has considered all relevant evidence, including that relating to the objective considerations." ....

Obviousness-Type Double Patenting At The USPTO

Obviousness-type double patenting is one of the items on a USPTO examiner's checklist of issues to consider when examining a patent application. MPEP § 804 provides guidance on this issue, and provides that, "[w]hen considering whether the invention defined in a claim of an application would have been an obvious variation of the invention defined in the claim of a patent, the disclosure of the patent may not be used as prior art." However, the MPEP states further, "This does not mean that one is precluded from all use of the patent disclosure." For example, according to the MPEP, permitted uses of the specification include "as a dictionary to learn the meaning of a term in the patent claim," and referring to "those portions of the specification which provide support for the patent claims."

Product Claims vs. Method Claims

While patent holders may welcome the discussion in this decision on the rationale behind Byck, Geneva, Pfizer, and Sun, those cases still leave applicants in a difficult position. A patent to a new product must disclose a practical use for that product in order to satisfy 35 USC §§ 101 and 112. If the patentee also wants to claim methods of using that product, it may be precluded from doing so by the doctrine of obviousness-type double patenting. One way to avoid this issue is to present both product and method claims in the original patent application. If the examiner issues a restriction requirement and requires the claims to be pursued in separate applications, 35 USC § 121 will shield the claims from obviousness-type double patenting, as long as the granted claims are consonant with the claims that were subject to the restriction requirement. Although this strategy does not work for every situation, it is one that applicants should keep in mind if they are interested in obtaining both product and method claims.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Leon Y. Lum
 
In association with
Related Video
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
Accounting and Audit
Anti-trust/Competition Law
Consumer Protection
Corporate/Commercial Law
Criminal Law
Employment and HR
Energy and Natural Resources
Environment
Family and Matrimonial
Finance and Banking
Food, Drugs, Healthcare, Life Sciences
Government, Public Sector
Immigration
Insolvency/Bankruptcy, Re-structuring
Insurance
Intellectual Property
International Law
Law Practice Management
Litigation, Mediation & Arbitration
Media, Telecoms, IT, Entertainment
Privacy
Real Estate and Construction
Strategy
Tax
Transport
Wealth Management
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.